



This Supplemental News Report is published as required, is part of the annual MERGENT INDUSTRIAL, OTC and OTCUNLISTED Manuals and will be included in the bound January 2019 Monthly News Reports and is published on our Website.

HOVERINK BIOTECHNOLOGIES INC

Company Website: <https://hoverinkbiotech.yolasite.com/>

History: Incorporated in Delaware on July 2, 2013, as Sky Run Acquisition Corporation. Name changed to Hoverink International Holdings on July 16, 2014. Present name adopted September 11, 2017.

Business Summary: Hoverink Biotechnologies is a development stage preclinical biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of LADAVRU® and biosimilars. Co.'s product candidate, LADAVRU®, focuses on patients suffering from cancer, cirrhosis, cirrhosis ascites, AIDS, and chronic pain, nausea and discomfort associated with chemotherapy particularly for patients using anthracyclines with the intention of targeting the treatment of relapsed or refractory AML. Anthracyclines are a class of chemotherapy drugs designed to disrupt the DNA of, and eventually destroy, targeted cancer cells.

Property: Co. maintains its principal executive offices in Los Angeles, CA.

Officers

Davidra Nicole Sajna, Chairman; President
Debbie Mae Carter, Chief Executive Officer; Chief Financial Officer; Treasurer
Cyrus Sajna, Vice President; Chief Operating Officer

Directors

Davidra Nicole Sajna, Chairman
Debbie Mae Carter, Director
Cyrus Sajna, Director

Auditors: MaloneBailey, LLP

Transfer Agent: VStock Transfer, LLC, Woodmere, NY

Shareholder Relations: Cyrus Sajna, Vice President Tel: 866-443-4666

No. of Stockholders: Jan. 7, 2019, 44

No. of Employees: Jan. 7, 2019, 3

Address: 1801 Century Park East 24th Floor, Los Angeles, CA 90067

Tel: 866 443-4666

Web: <https://hoverinkbiotech.yolasite.com/>

Email: info@hoverink.net

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017	2016	2015
General & administrative expenses	33,024	10,220	142,602
Professional fees	67,902	122,156	...
Management &			

director's fees	1,301,178	2,500	...
Travel & entertainment expenses	1,905
Stock based compensation expenses	1,375,400
Total operating expenses	2,777,504	134,876	144,507
Income (loss) from operations	(144,507)
Net income (loss) before income taxes	(2,777,504)	(134,876)	...
Net income (loss)	(2,777,504)	(134,876)	(144,507)
Weighted average shares outstanding - basic	23,962,137	13,872,000	13,872,000
Weighted average shares outstanding - diluted	23,962,137	13,872,000	13,872,000
Year end shares outstanding	66,772,000	13,872,000	13,872,000
Net earnings (loss) per share - basic	\$(0.12)	\$(0.01)	\$(0.01)
Net earnings (loss) per share - diluted	\$(0.12)	\$(0.01)	\$(0.01)
Total number of employees	3	3	...
Number of common stockholders	44

Reclassified to conform with 2017 presentation; As reported from the December 31, 2016 10K; Shares increased due to shares being issued for consulting fees; As of January 7, 2019

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017	2016	(revised)
Assets:			
Cash & cash equivalents	950
Prepaid expenses	16,007
Total current assets	16,957
Total assets	16,957
Liabilities:			
Accounts payable & accrued liabilities	1,499,396	189,015	189,015
Notes payable	35,000	35,000	35,000
Total current liabilities	1,534,396	224,014	224,014

Notes payable	17,000	...
Notes payable - related party	147,813	56,133
Total liabilities	1,699,209	280,148
Common stock	6,677	1,387
Additional paid in capital	1,370,130	20
Retained earnings (accumulated deficit)	(3,059,059)	(281,555)
Total stockholders' equity (deficit)	(1,682,252)	(280,148)

Reclassified to conform with 2017 presentation; As reported by the Company

Auditor's Report:

The following is an excerpt from the Report of the Independent Auditors, MaloneBailey, LLP, as it appeared in Co.'s Dec. 31, 2017 S-1:

"We have audited the accompanying balance sheets of Hoverink Biotechnologies, Inc. (the "Company") as of December 31, 2017 and 2016, and the related statements of operations, stockholders' deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

Debt: Dec. 31, 2017, \$164,813 (excluding current portion) comprised of:

- \$17,000 notes payable, due Nov 8, 2022.
- \$147,813 notes payable - related party, due Mar. 31, 2019 - Sept. 22, 2022.

Capital Stock: 1. Hoverink Biotechnologies Inc common; par \$ 0.0001.

AUTHORIZED—100,000,000 shs.

OUTSTANDING—Dec. 31, 2017, 66,772,000 shs; par \$ 0.0001.

Copyright©2019 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.